FDA
-
-
-
-
-
-
-
BofA Securities stays Underperform on ProKidney Corp. (PROK) after earnings on trial risk
-
-
-
-
-
-
-
ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates
-
-
-
-
-
-
-
ProKidney reports positive phase 2 trial results for kidney disease therapy
-
-
-
-
-
-
-
ProKidney to Participate in Two Upcoming Conferences: Evercore HealthCONx Conference and the Citi Global Healthcare Conference
-
-
-
-
-
-
-
ProKidney Announces Strategic Updates to its Phase 3 Program to Accelerate Rilparencel’s Registrational Path to Potential Approval in the U.S.
-
-
-
-
-
-
-
ProKidney Announces Proposed $125 Million Public Offering of Class A Ordinary Shares and Concurrent Registered Direct Offering
-
-
-
-
-
-
-
ProKidney Announces Key Leadership Appointments Strengthening Clinical and Technical Operations
-
328,148 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

